• There are no suggestions because the search field is empty.

Epredia and Aiforia announce partnership for global distribution of AI-powered pathology software

We are thrilled to announce our partnership with Epredia, a global leader in precision cancer diagnostics, for the global distribution of our AI-powered pathology software!
Written by Aiforia

Portsmouth, NH, USA, June 21, 2021 – Epredia, a global leader in precision cancer diagnostics, and Aiforia, a medical software company providing Artificial Intelligence (AI) based solutions for image analysis in pathology, have announced today that they have entered into a commercial distribution agreement for Aiforia’s comprehensive portfolio of workflow enhancing solutions which enable pathologists to harness the power of deep learning AI for image analysis.

Under the terms of this agreement, Epredia has been appointed as a global distribution partner for Aiforia’s portfolio of preclinical and clinical pathology tools, including segment exclusivity for distribution in Japan, Germany, UK, Italy, Spain, Sweden, Norway, Denmark, Iceland, France and the USA. From Summer 2021, Epredia will begin to commercialize the Aiforia portfolio of AI solutions. These solutions will be available as part of Epredia’s comprehensive digital pathology portfolio that already features the best-in-class CE-marked 3DHistech P1000 WSI scanner*.

Aiforia aims to equip pathologists with AI-powered, secure, and scalable cloud-based software for high precision image analysis that can be used in preclinical research and clinical diagnostics. Their solutions aim to enhance the speed and accuracy of pharmaceutical drug development and cancer diagnostics using intuitive, AI-powered software. Aiforia’s software currently has over 3,000 pathologists and scientists as users in over 50 countries.

Aiforia recently announced the CE-IVD marking for its Clinical AI Model for Breast Cancer: Ki67, a widely used key biomarker in breast cancer diagnostics, as part of the company’s upcoming Clinical Suites. The Aiforia Clinical Suites are under development to support the diagnosis of some of the world’s most prevalent cancers such as breast, lung, prostate, and more. The Suites, intended for release and regulatory filings over the coming years, are portfolios of powerful tools enabling pathologists to harness the power of AI to support them in accelerating sample review, enhancing diagnostic accuracy, and ultimately in improving patient outcomes.

Aiforia’s offering for preclinical assessment consists of bespoke AI model development services backed by Aiforia’s in-house science team using an intuitive cloud-based platform, catering to a wide range of therapy areas. Over 400 AI models for preclinical research have already been developed using Aiforia’s solutions.

“This alliance with Aiforia to commercialize their highly innovative portfolio of AI-based digital pathology solutions is another exciting step in building our presence in this growing area of cancer diagnostics,” explained John Sweeney, President, Epredia. “We are pleased to be adding the Aiforia offering to our portfolio of digital pathology solutions which now include cutting edge AI software from the largest players in the field bundled with our portfolio of best in class whole slide imaging scanners developed by 3DHistech. The product development expertise of Aiforia that has gone into these solutions ideally complements our global commercial reach and will enable us to bring their solutions to more pathologists across the world.”

“With their global presence in the pathology market and our expertise in delivering AI-based solutions for pathologists, Epredia is the ideal commercial partner to help us broaden the international reach of Aiforia’s powerful AI software to pathologists working in clinical diagnostics and preclinical drug development,” explained Jukka Tapaninen, Chief Executive Officer of Aiforia. “Our mission is to become a global leader in AI-assisted image analysis to improve the efficiencies of healthcare systems and enable better patient outcomes.”

* Regulatory requirements for the 3DHistech P1000 scanner and Aiforia's pathology solutions vary by country, please consult with your commercial partner to confirm the availability and approved use of the scanner and Aiforia's pathology solutions in your country.

About Epredia


Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, Epredia’s portfolio includes microscope slides, instruments and consumables. Epredia was established following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings in 2019. Epredia has major sites in the United States, the United Kingdom, Germany, Switzerland and China with a total of around 1,200 employees. Epredia is committed to achieving its mission to improve lives by enhancing cancer diagnostics for patients around the world. For further information on Epredia and its products, please visit www.epredia.com


About Aiforia


Aiforia equips pathologists and scientists in preclinical, academic, and clinical labs with deep learning artificial intelligence and cloud-based technology to increase the speed, accuracy, and consistency of analyzing large and complex medical images across a variety of fields from oncology to neuroscience. Aiforia is composed of a comprehensive mix of scientists experienced in a variety of medical areas from pathology to cancer diagnostics, software developers who collectively hold over 100 years' experience in artificial intelligence, and a business team with backgrounds in the pharmaceutical and biotechnology industries. Find out more about Aiforia at www.aiforia.com.


For more information, please contact:


Epredia Media:

Joseph Delahunty

PHC Group, Corporate Communications

Email: joseph.delahunty@ascensia.com


Aiforia Media:

Emma Vehviläinen

Head of Marketing, Aiforia

Email: emma.vehvilainen@aiforia.com